Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 05, 2023 09:15 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023

– Determination of Recommended Phase 2 Dose and Start of Phase 2 in 1Q 2023 for Oral Fadraciclib – – 2/3 Partial Responses in Lymphoma and 11/15 Stable Disease in Advanced Solid Tumors – – Expecting...